Personalized Management of Autoimmune Diseases With AI-Guided (GenAIS TM) Dietary Supplementation
NCT ID: NCT06470412
Last Updated: 2025-04-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
160 participants
INTERVENTIONAL
2023-02-02
2024-06-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of Synbiotic Supplementation on IL-10, TGF-B and Disease Activity in Systemic Lupus Erythematosus Patients
NCT07048470
Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLE
NCT04726553
Effect Of Curcuma Xanthorrhiza and Vitamin D3 Supplementation in SLE Patients With Hypovitamin D
NCT03155477
COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
NCT05000216
The Iguratimod Effect on Lupus Nephritis (IGeLU)
NCT02936375
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control Group
Control group
Participants receive supplement prescriptions from a physician based on current standard practices, which include biochemical markers, genetic data, and metabolic profiles.
AI-Guided Group
AI-Guided Group
Participants receive supplement prescriptions determined by GenAIS, an AI system which considers genetic data, metabolic profiles, biochemical markers, and patient history.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Control group
Participants receive supplement prescriptions from a physician based on current standard practices, which include biochemical markers, genetic data, and metabolic profiles.
AI-Guided Group
Participants receive supplement prescriptions determined by GenAIS, an AI system which considers genetic data, metabolic profiles, biochemical markers, and patient history.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Moderate to severe disease activity as indicated by standardized measures (e.g., DAS28 for rheumatoid arthritis, SLEDAI for lupus).
* Stable on existing autoimmune medication regimen for at least 3 months prior to the study.
* Willingness to provide genetic and metabolic data.
* Written informed consent.
Exclusion Criteria
* Significant medical conditions like severe renal, hepatic, or cardiovascular diseases that may interfere with the study outcomes.
* Use of dietary supplements that affect immune function within the last 3 months.
* Pregnancy or breastfeeding.
* Recent changes in autoimmune medication within the last 3 months.
* Participation in another clinical trial within the last 30 days.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Triangel Scientific
INDUSTRY
Center of New Medical Technologies
OTHER
S.LAB (SOLOWAYS)
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Center of New Medical Technologies
Novosibirsk, Novosibisk Region, Russia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SW015
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.